Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 1

Completed

Conditions: Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Salivary Gland Squamous Cell Carcinoma
Stage IVA Salivary Gland Cancer
Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IVC Salivary Gland Cancer
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Verrucous Carcinoma of the Larynx

Interventions: Drug: PI3K inhibitor BKM120
Biological: cetuximab

First Posted Date: 2013-03-22

Last Posted Date: 2021-10-05

Lead Sponsor: University of Chicago

Target Recruit Count: 12

Registration Number: NCT01816984

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Extensive Stage Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer

Interventions: Drug: topotecan hydrochloride
Drug: cyclodextrin-based polymer-camptothecin CRLX101

First Posted Date: 2013-03-04

Last Posted Date: 2020-06-26

Lead Sponsor: University of Chicago

Target Recruit Count: 29

Registration Number: NCT01803269

Locations: 🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
North Shore University Health System, Evanston, Illinois, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 2 locations

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Phase 1

Completed

Conditions: Monogenic Diabetes

Interventions: Drug: GLP-1
Drug: Exendin 9-39

First Posted Date: 2013-02-20

Last Posted Date: 2017-04-10

Lead Sponsor: University of Chicago

Target Recruit Count: 10

Registration Number: NCT01795144

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer

Not Applicable

Withdrawn

Conditions: Invasive Ductal Breast Carcinoma
Stage IB Breast Cancer
Ductal Breast Carcinoma in Situ
Stage IA Breast Cancer

Interventions: Procedure: magnetic resonance thermal imaging
Procedure: laser interstitial thermal therapy

First Posted Date: 2013-02-15

Last Posted Date: 2014-10-15

Lead Sponsor: University of Chicago

Registration Number: NCT01791998

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer

Not Applicable

Completed

Conditions: Stage II Prostate Carcinoma
Stage I Prostate Cancer

Interventions: Device: Visualase Thermal Therapy
Procedure: magnetic resonance imaging

First Posted Date: 2013-02-15

Last Posted Date: 2018-03-13

Lead Sponsor: University of Chicago

Target Recruit Count: 27

Registration Number: NCT01792024

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: sirolimus
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2013-02-13

Last Posted Date: 2019-04-22

Lead Sponsor: University of Chicago

Target Recruit Count: 56

Registration Number: NCT01791088

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Early Mobilization in the ICU

Not Applicable

Completed

Conditions: Respiratory Failure

Interventions: Other: early PT OT

First Posted Date: 2013-01-28

Last Posted Date: 2022-02-21

Lead Sponsor: University of Chicago

Target Recruit Count: 200

Registration Number: NCT01777035

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Effect of Azilsartan on Aldosterone in Postmenopausal Females

Not Applicable

Completed

Conditions: Hypertension

Interventions: Drug: Azilsartan medoximil
Drug: Placebo

First Posted Date: 2013-01-24

Last Posted Date: 2017-11-09

Lead Sponsor: University of Chicago

Target Recruit Count: 21

Registration Number: NCT01774591

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension

Phase 1

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Placebo
Drug: Ranolazine

First Posted Date: 2012-12-31

Last Posted Date: 2017-03-03

Lead Sponsor: University of Chicago

Target Recruit Count: 12

Registration Number: NCT01757808

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Dexamethasone and Block Duration in Upper Extremity

Not Applicable

Terminated

Conditions: Duration of Pain Relief

Interventions: Drug: Dexamthsone
Drug: Bupivacaine

First Posted Date: 2012-12-27

Last Posted Date: 2019-05-14

Lead Sponsor: University of Chicago

Target Recruit Count: 5

Registration Number: NCT01756573

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy